Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Cancer Recurrent × Carboplatin × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 323 Lung Neoplasms 174 Breast Neoplasms 142 Ovarian Neoplasms 115 Triple Negative Breast Neoplasms 69 Squamous Cell Carcinoma of Head and Neck 68 Small Cell Lung Carcinoma 60 Fallopian Tube Neoplasms 50 Carcinoma, Ovarian Epithelial 41 Head and Neck Neoplasms 39 Neoplasms 37 Neoplasm Metastasis 37 Adenocarcinoma of Lung 32 Esophageal Neoplasms 30 Prostatic Neoplasms 26 Esophageal Squamous Cell Carcinoma 25 Endometrial Neoplasms 24 Uterine Cervical Neoplasms 21 Carcinoma, Squamous Cell 21 Brain Neoplasms 21 Lymphoma, Large B-Cell, Diffuse 19 Urinary Bladder Neoplasms 18 Recurrence 18 Central Nervous System Neoplasms 18 Lymphoma 17 Neuroblastoma 15 Melanoma 15 Carcinoma 15 Adenocarcinoma, Bronchiolo-Alveolar 15 Testicular Neoplasms 13

Interventions

Paclitaxel 2 Tocotrienols 1 Platinum Compounds 1 EP-100 membrane-disrupting peptide 1 Carboplatin 1 Bevacizumab 1 AC 7700 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01332656 2015-12-21

OPSALIN

Sanofi

Phase 2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡